{"id":{"repo_id":"uic","oai_identifier":"oai:figshare.com:article/30426514"},"canonical_url":"https://search.dev.ndltd.org/etd/uic/oai:figshare.com:article/30426514","repository":{"repo_id":"uic","name":"University of Illinois - Chicago","base_url":"https://api.figshare.com/v2/oai"},"display":{"title":"Engineered Anti-CD40 Agonist Antibody for Cancer Vaccine Delivery","abstract":"Cancer vaccines targeting patient-derived neoantigens offer great promise for personalized cancer therapy but face challenges in achieving targeted delivery to antigen-presenting cells (APCs) to elicit robust and durable cancer-specific immune responses. We synthesized an anti-mouse CD40 agonistic–monovalent streptavidin fusion antibody (αCD40-mSAs), which enables targeted delivery of biotinylated neoantigen peptides to APCs in draining lymph nodes (dLNs). αCD40-mSAs were validated for mSA expression and demonstrated strong binding affinities to mouse CD40 and biotin. Advanced imaging demonstrated that αCD40-mSAs enhances homing to dLNs and intracellular delivery of neoantigen peptides to critical APC subsets, such as cDC1. The potent agonistic effects of αCD40-mSAs on dendritic cell maturation, activation, and antigen presentation were verified through in vitro assays. Vaccination with αCD40-mSAs elicited robust cancer-specific CD8⁺ T cell responses, leading to significant tumor regression and prevention in a mouse tumor model. These results support αCD40-mSAs as an 'all-in-one' vaccine delivery platform with multifunctional immunopharmacological advantages and strong translational potential for personalized cancer vaccination.","abstract_html":"Cancer vaccines targeting patient-derived neoantigens offer great promise for personalized cancer therapy but face challenges in achieving targeted delivery to antigen-presenting cells (APCs) to elicit robust and durable cancer-specific immune responses. We synthesized an anti-mouse CD40 agonistic–monovalent streptavidin fusion antibody (αCD40-mSAs), which enables targeted delivery of biotinylated neoantigen peptides to APCs in draining lymph nodes (dLNs). αCD40-mSAs were validated for mSA expression and demonstrated strong binding affinities to mouse CD40 and biotin. Advanced imaging demonstrated that αCD40-mSAs enhances homing to dLNs and intracellular delivery of neoantigen peptides to critical APC subsets, such as cDC1. The potent agonistic effects of αCD40-mSAs on dendritic cell maturation, activation, and antigen presentation were verified through in vitro assays. Vaccination with αCD40-mSAs elicited robust cancer-specific CD8⁺ T cell responses, leading to significant tumor regression and prevention in a mouse tumor model. These results support αCD40-mSAs as an 'all-in-one' vaccine delivery platform with multifunctional immunopharmacological advantages and strong translational potential for personalized cancer vaccination.","abstract_has_math":false,"creators":["Dahee Jung (3357377)"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2025,"date_issued":"2025-08-01T00:00:00Z","date_published":"2025-08-01T00:00:00Z","updated_at":"2026-07-27T21:35:00Z","subjects":["Health Sciences","Immunology"],"languages":[],"rights":["In Copyright","Open Access after 2027-09-01"],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"https://doi.org/10.25417/uic.30426514.v1","outbound_label":"DOI","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:creator","label":"Author","values":["Dahee Jung (3357377)"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2025-08-01T00:00:00Z"]},{"key":"dc:relation","label":"Dc Relation","values":["https://figshare.com/articles/thesis/Engineered_Anti-CD40_Agonist_Antibody_for_Cancer_Vaccine_Delivery/30426514"]},{"key":"dc:type","label":"Dc Type","values":["Text","Thesis"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Health Sciences","Immunology"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:rights","label":"Dc Rights","values":["In Copyright","Open Access after 2027-09-01"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["10.25417/uic.30426514.v1"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Cancer vaccines targeting patient-derived neoantigens offer great promise for personalized cancer therapy but face challenges in achieving targeted delivery to antigen-presenting cells (APCs) to elicit robust and durable cancer-specific immune responses. We synthesized an anti-mouse CD40 agonistic–monovalent streptavidin fusion antibody (αCD40-mSAs), which enables targeted delivery of biotinylated neoantigen peptides to APCs in draining lymph nodes (dLNs). αCD40-mSAs were validated for mSA expression and demonstrated strong binding affinities to mouse CD40 and biotin. Advanced imaging demonstrated that αCD40-mSAs enhances homing to dLNs and intracellular delivery of neoantigen peptides to critical APC subsets, such as cDC1. The potent agonistic effects of αCD40-mSAs on dendritic cell maturation, activation, and antigen presentation were verified through in vitro assays. Vaccination with αCD40-mSAs elicited robust cancer-specific CD8⁺ T cell responses, leading to significant tumor regression and prevention in a mouse tumor model. These results support αCD40-mSAs as an 'all-in-one' vaccine delivery platform with multifunctional immunopharmacological advantages and strong translational potential for personalized cancer vaccination."]},{"key":"dc:title","label":"Title","values":["Engineered Anti-CD40 Agonist Antibody for Cancer Vaccine Delivery"]}]}],"canonical_facts":{"dc:creator":["Dahee Jung (3357377)"],"dc:date":["2025-08-01T00:00:00Z"],"dc:description":["Cancer vaccines targeting patient-derived neoantigens offer great promise for personalized cancer therapy but face challenges in achieving targeted delivery to antigen-presenting cells (APCs) to elicit robust and durable cancer-specific immune responses. We synthesized an anti-mouse CD40 agonistic–monovalent streptavidin fusion antibody (αCD40-mSAs), which enables targeted delivery of biotinylated neoantigen peptides to APCs in draining lymph nodes (dLNs). αCD40-mSAs were validated for mSA expression and demonstrated strong binding affinities to mouse CD40 and biotin. Advanced imaging demonstrated that αCD40-mSAs enhances homing to dLNs and intracellular delivery of neoantigen peptides to critical APC subsets, such as cDC1. The potent agonistic effects of αCD40-mSAs on dendritic cell maturation, activation, and antigen presentation were verified through in vitro assays. Vaccination with αCD40-mSAs elicited robust cancer-specific CD8⁺ T cell responses, leading to significant tumor regression and prevention in a mouse tumor model. These results support αCD40-mSAs as an 'all-in-one' vaccine delivery platform with multifunctional immunopharmacological advantages and strong translational potential for personalized cancer vaccination."],"dc:identifier":["10.25417/uic.30426514.v1"],"dc:relation":["https://figshare.com/articles/thesis/Engineered_Anti-CD40_Agonist_Antibody_for_Cancer_Vaccine_Delivery/30426514"],"dc:rights":["In Copyright","Open Access after 2027-09-01"],"dc:subject":["Health Sciences","Immunology"],"dc:title":["Engineered Anti-CD40 Agonist Antibody for Cancer Vaccine Delivery"],"dc:type":["Text","Thesis"]},"updated_at":"2026-07-27T21:35:00Z"}